← All trials
NCT05493163
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 19, 2022
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2028
- First posted
- Aug 9, 2022
- Last posted
- Nov 8, 2022
- Enrollment
- 558
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Teaching Hospital Královské Vinohrady (FNKV)Lead sponsor
- Charles UniversityCollaborator
- Teaching Hospital Královské Vinohrady (FNKV)Reponsible party - principal investigator
- Charles UniversityCollaborator
- University Hospital BrnoCollaborator
- University Hospital BrnoCollaborator
- Palacky UniversityCollaborator
- University of OstravaCollaborator
- University of PilsenCollaborator
- Teaching Hospital Královské Vinohrady (FNKV)Sponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.